Skip to main content
Log in

4-Aminopyridine and cerebellar gait: a retrospective case series

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Alvina K, Khodakhah K (2010) The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 30:7258–7268

    Article  PubMed  CAS  Google Scholar 

  2. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494–502

    Article  PubMed  CAS  Google Scholar 

  3. Hausdorff JM (2005) Gait variability: methods, modeling and meaning. J Neuroeng Rehabil 2:19

    Article  PubMed  Google Scholar 

  4. Ilg W, Brotz D, Burkard S, Giese MA, Schols L, Synofzik M (2010) Long-term effects of coordinative training in degenerative cerebellar disease. Mov Disord 25:2239–2246

    Article  PubMed  Google Scholar 

  5. Ilg W, Golla H, Thier P, Giese MA (2007) Specific influences of cerebellar dysfunctions on gait. Brain 130:786–798

    Article  PubMed  Google Scholar 

  6. Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L (2009) Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73:1823–1830

    Article  PubMed  CAS  Google Scholar 

  7. Kalla R, Glasauer S, Buttner U, Brand T, Strupp M (2007) 4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 130:2441–2451

    Article  PubMed  Google Scholar 

  8. Schniepp R, Wuehr M, Ackl N, Danek A, Brandt T, Strupp M, Jahn K (2011) 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J Neurol 258:1708–1711

    Article  PubMed  Google Scholar 

  9. Schniepp R, Wuehr M, Neuhaeusser M, Kamenova M, Dimitriadis K, Klopstock T, Strupp M, Brandt T, Jahn K (2012) Locomotion speed determines gait variability in cerebellar ataxia and vestibular failure. Mov Disord 27(1):125–131

    Article  PubMed  Google Scholar 

  10. Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62:1623–1625

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Judy Benson for copy-editing the manuscript. The work was supported by the German research foundation (Deutsche Forschungsgemeinschaft, DFG JA 1087/1-1), the German Hertie Foundation and the Federal Ministry for Education and Science (BMBF 01EO0901) of Germany.

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical standard

This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roman Schniepp.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schniepp, R., Wuehr, M., Neuhaeusser, M. et al. 4-Aminopyridine and cerebellar gait: a retrospective case series. J Neurol 259, 2491–2493 (2012). https://doi.org/10.1007/s00415-012-6595-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-012-6595-2

Keywords

Navigation